JW Therapeutics
JW Therapeutics, a Juno and WuXi AppTec joint venture, made relma-cel, the first CAR-T developed and manufactured in China to be approved.
Overview
Relmacabtagene autoleucel (Carteyva) approved 2021 for large B-cell lymphoma and 2022 for follicular lymphoma; pipeline in mantle cell lymphoma, leukaemia and autoimmune disease. Its commercial struggle (list price around CN¥ 1.29 million, not NRDL-listed, provincial supplementary insurance filling some of the gap) is the case study for how China pays for cell therapy.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +6
Pages like this
not linked directly; found by shared links- CompanyWuXi Biologics
Shares Ge Li, WuXi AppTec and the tag china.
- ProductInaticabtagene autoleucel
Shares CAR-T cell therapy and the tag china.
- InstitutionPeking University People's Hospital
Shares CAR-T cell therapy and the tag china.
- TrialLUMMICAR STUDY 1
Shares CAR-T cell therapy and the tag china.
- InstitutionInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Shares CAR-T cell therapy and the tag china.
- CompanyIASO Biotherapeutics
Shares CAR-T cell therapy and the tag china.
- InstitutionNational Healthcare Security Administration
Shares Prices and value and the tag china.
- InstitutionRenji Hospital, Shanghai Jiao Tong University
Shares CAR-T cell therapy and the tag china.